Coverage and drug adherence in 5-year survivors
In 5-year survivors, a low proportion had not been covered by RASi (HFC: 3.0%; PC: 2.2%) and BB (HFC: 2.1%; PC: 3.1%) during the 5 years of follow-up, and among individuals covered with RASi or BB the PDC-level for both drugs was high (